



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2021/061180

(22) International Filing Date:
30 November 2021 (30.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/119,359 30 November 2020 (30.11.2020) US

(71) Applicant: CORNELL UNIVERSITY [US/US]; Center
For Technology Licensing ("CTL") at, Cornell University,
395 Pine Tree Road, Suite 310, Ithaca, NY 14850 (US).

(72) Inventors: BANDER, Neil, H.; 6 Old Oak Lane, PO
Box 944, Quogue, NY 11959 (US). LECONET, Wilhelm;
Arthur van Schendelstraat 747, 3511 MZ Utrecht (NL).
GUO, Ming; 23 Elm Street, Tenafly, NJ 07670 (US). LIU,
He; 450 East 63rd Street, 7N, New York, NY 10065 (US).

LORENZ, Ivo; 150 Myrtle Avenue, Apt 3003, Brooklyn,
NY 11201 (US). KHAN, Abdul, G.; 13010 Ridgeline Blvd,
Apt 2206, Cedar Park, TX 78613 (US).

(74) Agent: GOLDMAN, Michael, L. et al.; Troutman Pep-
per Hamilton Sanders LLP, 70 Linden Oaks, Suite 210,
Rochester, NY 14625 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION

Strict acceptor substrate specificity of glycosyltransferases




FIG. 1

(57) Abstract: The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*